Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
8.49
-0.28 (-3.19%)
At close: Mar 9, 2026, 4:00 PM EDT
8.33
-0.16 (-1.88%)
After-hours: Mar 9, 2026, 7:50 PM EDT
Karyopharm Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 156 | 135 | 85 | 99 | 385 | 486 | |
| Market Cap Growth | 102.26% | 57.91% | -13.86% | -74.26% | -20.76% | -57.36% | |
| Enterprise Value | 398 | 359 | 220 | 201 | 549 | 595 | |
| Last Close Price | 8.49 | 7.36 | 10.14 | 12.97 | 51.00 | 96.45 | |
| PS Ratio | 1.07 | 0.92 | 0.59 | 0.68 | 2.45 | 2.32 | |
| PB Ratio | - | -0.46 | -0.46 | -0.73 | -23.11 | -6.10 | |
| EV/Sales Ratio | 2.72 | 2.46 | 1.51 | 1.38 | 3.50 | 2.84 | |
| Debt / Equity Ratio | -1.04 | -1.04 | -1.44 | -2.27 | -18.72 | -3.94 | |
| Net Debt / Equity Ratio | -0.83 | -0.83 | -0.86 | -0.87 | -2.03 | -1.07 | |
| Net Debt / EBITDA Ratio | -2.68 | -2.68 | -1.34 | -0.91 | -0.24 | -0.87 | |
| Net Debt / FCF Ratio | -3.21 | -3.21 | -1.25 | -1.27 | -0.23 | -0.79 | |
| Asset Turnover | 1.07 | 1.07 | 0.72 | 0.49 | 0.47 | 0.68 | |
| Inventory Turnover | 29.98 | 29.98 | 38.35 | 39.55 | 36.95 | 1.01 | |
| Quick Ratio | 0.98 | 0.98 | 1.51 | 3.16 | 5.05 | 3.43 | |
| Current Ratio | 1.12 | 1.12 | 1.70 | 3.37 | 5.31 | 3.74 | |
| Return on Assets (ROA) | -41.56% | -41.56% | -36.88% | -27.05% | -26.79% | -19.86% | |
| Return on Capital Employed (ROCE) | -554.60% | -554.60% | -165.50% | -75.80% | -48.70% | -42.40% | |
| Earnings Yield | -125.88% | -145.47% | -89.55% | -144.44% | -42.94% | -25.55% | |
| FCF Yield | -48.39% | -55.93% | -149.55% | -93.59% | -38.88% | -22.09% | |
| Buyback Yield / Dilution | -29.33% | -29.33% | -11.02% | -39.54% | -8.85% | -4.41% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.